Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
- Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona
- Jefferies 2016 London Healthcare Conference on November 16 in London
- Citi 2016 Global Healthcare Conference on December 8 in New York City
SAN RAFAEL, Calif., Nov. 03, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Credit Suisse 25th Annual Healthcare Conference on November 7, 2016 at 10:00am MT/12:00pm ET, in Scottsdale, Arizona. Management will also participate in the Jefferies 2016 London Healthcare Conference on November 16, 2016, in London and the Citi 2016 Global Healthcare Conference on December 8, 2016 at 8:45am ET, in New York City. Webcasts will be available for the Credit Suisse and Citi conferences. To access the live webcasts, please visit the investor section of the BioMarin website, www.BMRN.com. A replay will also be archived on the site for at least one week following the event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
